Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Liraglutide’s efficacy in type 2 diabetes varies with metabolic state, engaging brain-mediated insulin secretion in healthy individuals, direct islet action in glucose intolerance, and insulin-independent pathways in advanced disease stages
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1
A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo
A 2025 meta-analysis of 19 RCTs (n=1657) found liraglutide combined with metformin improved glycaemia, insulin resistance, BMI, sex hormones and lipids versus metformin alone in overweight or obese women with PCOS; evidence certainty was lo
This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.